Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Operating margin
Smith & Nephew SNATS, Inc.'s operating margin over the twelve months to 30 June 2023 was 0.00%. Over the past ten years it has ranged from 6.47% (fiscal 2020) to 19.6% (fiscal 2017); the current reading is higher than 55% of that period. That is above the Medical Devices industry median of −15.1% and in line with the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 12.9% | 1.57 |
| FY2024 | 11.3% | 3.65 |
| FY2023 | 7.66% | (0.97) |
| FY2022 | 8.63% | (2.75) |
| FY2021 | 11.4% | 4.91 |
| FY2020 | 6.47% | (9.39) |
| FY2019 | 15.9% | (1.74) |
| FY2018 | 17.6% | (2.00) |
| FY2017 | 19.6% | 2.44 |
| FY2016 | 17.2% | 3.61 |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| Jun 2022 | 0.00% | 0.00 |
| Dec 2021 | 0.00% | 0.00 |
| 6 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| GMED Globus Medical, Inc. compare | 21.7% |
| PODD Insulet Corporation compare | 18.4% |
| PEN Penumbra, Inc. compare | 12.1% |
| SNN Smith & Nephew SNATS, Inc. | 0.00% |
| BRKR Bruker Corporation compare | −1.99% |
| BIO.B Bio-Rad Laboratories, Inc. compare | −2.39% |
| BIO Bio-Rad Laboratories, Inc. compare | −2.39% |
| TXG 10x Genomics compare | −14.3% |
| GKOS Glaukos Corporation compare | −25.5% |
| Medical Devices industry median | −15.1% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement